Introduction of a New Proprietary PET Drug in a Changing Manufacturing Environment

John Lister-James, Ph.D.
Avid Radiopharmaceuticals, Inc.
Florbetapir F 18 (\(^{18}\)F AV-45)

- In development for imaging beta-amyloid deposits in the brain – now in Phase 3
- Clinical trials supported by multiple collaborating manufacturers/manufacturing sites
- Initial challenge:
  - installation of CTM manufacture into commercial operations focused on FDG
  - new equipment/process/procedures/documentation
- Training, training, training
- Successfully achieved – IND and USP <823>
Commercial manufacturing environment
• Changing from USP <823> to 21 CFR Part 212

New product:
• NDA submission and eventual commercial production before December 2011
• Processes/procedures/documentation consistent with regulatory compliance and efficient operations
• Planning for operations under 21 CFR Part 212